Pacira BioSciences (STU:82P) Tariff Resilience Score: 8/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:82P Pacira BioSciences Inc STU:82P
75 GF Score
Price €22.80
GF Value €25.82
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Tariff Resilience Score?

Pacira BioSciences STU:82P -2.56% 75 Tariff Resilience Score is 8 as of Aug. 01, 2026. GuruFocus rates STU:82P with a GF Score™ of 75/100 and a GF Value™ of €25.82 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,027 Drug Manufacturers companies, Pacira BioSciences ranks better than 99.61% on this metric.

Pacira BioSciences has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Pacira BioSciences has Pacira BioSciences primarily operates within the U.S., reducing its exposure to international tariffs. Its focus on domestic markets and limited reliance on imports enhance its resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Pacira BioSciences might have Highly Resilient.

Pacira BioSciences  (STU:82P) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Pacira BioSciences Tariff Resilience Score Related Terms

STU:82P vs ALVO, BIOA, COLL: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacira BioSciences Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Tariff Resilience Score falls into.


STU:82P
75GF Score
Pacira BioSciences Inc STU:82P
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Pacira BioSciences (STU:82P) has a Tariff Resilience Score of 8 as of Aug. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Pacira BioSciences ranks #4 out of 1027 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Pacira BioSciences' Tariff Resilience Score too high?
Pacira BioSciences' current Tariff Resilience Score is 8. Based on the distribution chart, Pacira BioSciences ranks #4 out of 1027 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Tariff Resilience Score compare to ALVO and BIOA?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #4 out of 1027 companies for Tariff Resilience Score. This places Pacira BioSciences in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Pacira BioSciences's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (STU:82P) is currently considered Modestly Undervalued. The stock's GF Value™ is €25.82, compared to a current price of €22.80 — trading 11.7% below its estimated fair value. The current Tariff Resilience Score is 8. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Pacira BioSciences (STU:82P), the current Tariff Resilience Score is 8 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (STU:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.80 is trading 11.7% below its estimated GF Value™ of €25.82. GuruFocus considers Pacira BioSciences to be Modestly Undervalued.

Key valuation signals for STU:82P:

  • Tariff Resilience Score: 8
  • GF Value™: €25.82 vs. price of €22.80 (11.7% below fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the STU:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score

Get the complete analysis for STU:82P

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price
€25.82
GF Value